Summary
Vertex Pharmaceuticals Incorporated has filed an 8-K report detailing the conversion of all outstanding 5.75% Convertible Senior Subordinated Notes due in February 2011. As of February 2, 2007, approximately $59.6 million in principal amount of these notes was converted into shares of Vertex's common stock. This conversion was executed at a rate of $14.94 per share, resulting in the issuance of 3,992,473 new shares of common stock. The company states this transaction was exempt from registration under Section 3(a)(9) of the Securities Act of 1933, as it involved exchanges with existing security holders without any commission or remuneration paid. This event effectively eliminates the company's convertible debt maturing in 2011, simplifying its capital structure and removing future interest payment obligations associated with these notes. For investors, this means a slight dilution of ownership due to the issuance of new shares, but also a reduction in financial leverage and a clearer path forward without this specific debt instrument. The conversion price of $14.94 per share provides insight into the market valuation at the time the notes were called for redemption.
Key Highlights
- 1Vertex Pharmaceuticals announced the full conversion of its 5.75% Convertible Senior Subordinated Notes due in February 2011.
- 2Approximately $59.6 million in aggregate principal amount of these notes has been converted.
- 3The conversion was executed at a price of $14.94 per share.
- 4Vertex issued 3,992,473 shares of its common stock as a result of the conversion.
- 5The company states the conversion is exempt from registration under Section 3(a)(9) of the Securities Act of 1933.
- 6This event eliminates Vertex's convertible debt maturing in 2011.